Evommune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	60.03	44.06	16.26	29.02
Short-Term Investments	140.76	105.14	55.79	50.06
Cash & Short-Term Investments	200.79	149.2	72.04	79.08
Cash Growth	131.34%	107.11%	-8.91%	-
Other Current Assets	3.45	4.28	1.95	0.95
Total Current Assets	204.25	153.48	73.99	80.03
Net Property, Plant & Equipment	9.22	2.46	1.8	1.97
Long-Term Investments	87.21	67.49	-	-
Other Long-Term Assets	1.27	1.52	0.27	0.25
Total Assets	301.95	224.95	76.06	82.25
Accounts Payable	5.04	7.76	8.26	1.76
Accrued Expenses	10.69	9.55	6.73	4.03
Current Portion of Leases	1.24	0.24	0.49	0.77
Unearned Revenue	-	-	3	-
Other Current Liabilities	0.52	0.36	9.5	0.3
Total Current Liabilities	17.49	17.91	27.98	6.86
Long-Term Leases	6.44	1.29	-	0.49
Other Long-Term Liabilities	0.43	0.18	0.54	3.25
Total Long-Term Liabilities	6.87	1.47	0.54	3.73
Total Liabilities	24.36	19.38	28.52	10.59
Common Stock	0	0	-	-
Additional Paid-in Capital	552.59	426.65	7.98	6.2
Retained Earnings	-275.01	-221.09	-152.22	-83.91
Total Common Shareholders' Equity	277.59	205.57	-144.24	-77.71
Minority Interest	-	-	191.78	149.37
Shareholders' Equity	277.59	205.57	47.54	71.66
Total Liabilities & Equity	301.95	224.95	76.06	82.25
Total Debt	7.68	1.53	0.49	1.26
Net Cash (Debt)	193.12	147.67	71.55	77.83
Net Cash Growth	122.68%	106.38%	-8.06%	-
Net Cash Per Share	8.48	24.06	47.44	62.10
Book Value	277.59	205.57	-144.24	-77.71
Book Value Per Share	12.18	33.50	-95.63	-62.01
Tangible Book Value	277.59	205.57	-144.24	-77.71
Tangible Book Value Per Share	12.18	33.50	-95.63	-62.01

SEC Filings: 10-K · 10-Q